Literature DB >> 19156489

Left ventricular long-axis function in myasthenia gravis.

Jone Furlund Owe1, Einar Skulstad Davidsen, Geir Egil Eide, Eva Gerdts, Nils Erik Gilhus.   

Abstract

Myasthenia gravis (MG) primarily affects skeletal muscles, but influence on cardiac function has been suggested. The aim of this study was to assess left ventricular long-axis function in MG patients compared to healthy controls, and to examine whether any MG-related heart involvement was influenced by the acetylcholine-esterase inhibitor pyridostigmine. We found that early diastolic atrioventricular-plane velocity and tissue Doppler peak systolic strain was lower in MG patients than in controls before pyridostigmine. The differences disappeared following administration of pyridostigmine. Also, tissue velocities at systole and early diastole tended to be lower in patients before pyridostigmine. In multivariate analyses adjusting for between-group differences in blood pressure, MG was no longer associated with lower longaxis function. Conventional echocardiographic measures of left ventricular diastolic and systolic function did not differ between groups. In conclusion, this study, using modern tissue Doppler imaging as well as conventional echocardiography, could not demonstrate definite MG-related cardiac involvement in a group of MG patients without known cardiac disease, but indicates that pyridostigmine-responsive MG-related alterations in cardiac muscle function exist in MG patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19156489     DOI: 10.1007/s00415-008-0049-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

Review 1.  Titin and ryanodine receptor antibodies in myasthenia gravis.

Authors:  G O Skeie; J A Aarli; N E Gilhus
Journal:  Acta Neurol Scand Suppl       Date:  2006

2.  Left ventricular function in myasthenia gravis.

Authors:  K A Johannessen; A Mygland; N E Gilhus; J Aarli; H Vik-Mo
Journal:  Am J Cardiol       Date:  1992-01-01       Impact factor: 2.778

Review 3.  Autoimmunity against the ryanodine receptor in myasthenia gravis.

Authors:  G O Skeie; P K Lunde; O M Sejersted; A Mygland; J A Aarli; N E Gilhus
Journal:  Acta Physiol Scand       Date:  2001-03

4.  [Myasthenia gravis with myocarditis and sudden death].

Authors:  H Hofstad; N E Gilhus; J A Aarli; H Gjengstø; S J Mørk; J E Varhaug
Journal:  Tidsskr Nor Laegeforen       Date:  1987-05-30

5.  Impaired left ventricular diastolic filling in patients with coronary artery disease: assessment with radionuclide angiography.

Authors:  R O Bonow; S L Bacharach; M V Green; K M Kent; D R Rosing; L C Lipson; M B Leon; S E Epstein
Journal:  Circulation       Date:  1981-08       Impact factor: 29.690

6.  Pericarditis in myasthenia gravis.

Authors:  Hemender S Vats; Steven K Richardson; Satyavardhan Pulukurthy; Brian Olshansky
Journal:  Cardiol Rev       Date:  2004 May-Jun       Impact factor: 2.644

7.  Antibodies against beta1 and beta2 adrenergic receptors in myasthenia gravis.

Authors:  B Y Xu; R Pirskanen; A K Lefvert
Journal:  J Neuroimmunol       Date:  1998-11-02       Impact factor: 3.478

8.  Heart muscle antibodies in myasthenia gravis.

Authors:  A Mygland; J A Aarli; H Hofstad; N E Gilhus
Journal:  Autoimmunity       Date:  1991       Impact factor: 2.815

9.  Left ventricular volumes determined by two-dimensional echocardiography in a normal adult population.

Authors:  D W Wahr; Y S Wang; N B Schiller
Journal:  J Am Coll Cardiol       Date:  1983-03       Impact factor: 24.094

10.  Electrocardiographic findings in 24 patients with myasthenia gravis.

Authors:  K Büyüköztürk; C Ozdemir; D Kohen
Journal:  Acta Cardiol       Date:  1976       Impact factor: 1.718

View more
  5 in total

1.  Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study.

Authors:  J B Andersen; J F Owe; A Engeland; N E Gilhus
Journal:  Eur J Neurol       Date:  2014-04-09       Impact factor: 6.089

2.  Association of Cardiac Autonomic Responses with Clinical Outcomes of Myasthenia Gravis: Short-Term Analysis of the Heart-Rate and Blood Pressure Variability.

Authors:  Monika Zawadka-Kunikowska; Łukasz Rzepiński; Małgorzata Tafil-Klawe; Jacek J Klawe; Paweł Zalewski; Joanna Słomko
Journal:  J Clin Med       Date:  2022-06-27       Impact factor: 4.964

3.  Cardiac Autonomic Dysfunction in Myasthenia Gravis and Relapsing-Remitting Multiple Sclerosis-A Pilot Study.

Authors:  Łukasz Rzepiński; Monika Zawadka-Kunikowska; Julia L Newton; Paweł Zalewski
Journal:  J Clin Med       Date:  2021-05-18       Impact factor: 4.241

4.  Defining Features of Patients who Develop Takotsubo Cardiomyopathy during Myasthenic Crisis: A Systematic Review of Case Studies.

Authors:  Pramod Theetha Kariyanna; Bayu Sutarjono; Apoorva Jayarangaiah; Remi Okwechime; Amog Jayarangaiah; Perry Wengrofsky; Isabel M McFarlane
Journal:  Am J Med Case Rep       Date:  2019-07-19

5.  A Broken Heart: Cardiac Arrest As the Initial Presentation of Myasthenic Crisis.

Authors:  Alexander Andreev; Farhana Begum; Anjuli Singh; Sonu Sahni
Journal:  Cureus       Date:  2020-02-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.